Advanced RP-L102 for Fanconi Anemia towards regulatory reviews; EMA accepted MAA for review and BLA submission anticipated in the first half of 2024
Continued preparations to launch LV portfolio.
For the readers interested in the stock health of Rocket Pharmaceuticals Inc. (RCKT). It is currently valued at $17.23. When the transactions were called off in the previous session, Stock hit the highs of $17.575, after setting-off with the price of $17.33. Company’s stock value dipped to $16.54
Continued to advance clinical gene therapy programs for the treatment of Danon Disease, Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I) and Pyruvate Kinase Deficiency (PKD) Updates on all four programs to be presented at the 2022 Annual Meeting of the American Society of Gene and Cell Therapy (ASGC.
Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M D to its Scientific Advisory Board forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.